Alnylam Pharmaceuticals Inc (ALNY)vsCentury Therapeutics Inc (IPSC)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
IPSC
Century Therapeutics Inc
$2.24
-5.49%
HEALTHCARE · Cap: $434.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3302% more annual revenue ($3.71B vs $109.16M). ALNY leads profitability with a 8.5% profit margin vs -8.8%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
IPSC
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for IPSC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.0% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : IPSC
The strongest argument for IPSC centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while IPSC is a turnaround play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.72 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 27/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company dedicated to advancing allogenic cell therapies that aim to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the company is developing innovative off-the-shelf therapeutic solutions designed to improve both patient outcomes and accessibility. With a strong pipeline of clinical-stage product candidates and strategic collaborations enhancing its competitive advantage, Century Therapeutics is well-positioned to drive innovation in the rapidly expanding cell therapy landscape, presenting compelling potential for clinical breakthroughs and favorable shareholder returns.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?